Publications by authors named "Caroline Algrin"
Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.
Clin Exp Rheumatol
July 2022
Article Synopsis
- The study investigates the prevalence of venous thromboembolism (VTE) in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) and systemic inflammatory autoimmune diseases (SIADs).
- The results show that 21.6% of patients developed VTE during a follow-up period, with MDS/CMML progression being a significant risk factor.
- There was no significant difference in overall survival or leukemia-free survival between patients with VTE and those without, highlighting the serious but not necessarily fatal implications of VTE in this patient group.
Monoclonal immunoglobulin M (IgM) anti-myelin-associated glycoprotein (MAG) neuropathy is a rare disabling condition, most commonly treated with rituximab monotherapy (R), which leads to neurological improvement in only 30%-50% of patients. The combination of rituximab plus chemotherapy has been proven to improve the level of responses. We studied the outcomes of anti-MAG neuropathy patients treated either by R, or by immunochemotherapy (ICT) in our centre, focusing on the incidence of the first neurological response evaluated by the modified Rankin scale (mRS).
View Article and Find Full Text PDFArticle Synopsis
- R-CHOP immuno-chemotherapy is effective for treating diffuse large B-cell lymphoma (DLBCL), but a significant percentage (30-40%) of patients either don't respond or relapse.
- Researchers have identified the protein CYCLON as a key factor linked to disease progression and treatment resistance in DLBCL, establishing it as a potential predictor of poor outcomes.
- The study also highlights the interaction between CYCLON and NPM1, suggesting that their co-expression and specific locations within the cell could provide insights for developing more tailored treatment strategies for high-risk DLBCL patients.
Article Synopsis
- Diffuse large B-cell lymphoma (DLBCL) is a diverse cancer type treated primarily with the R-CHOP immuno-chemotherapy regimen, but about 30% of patients do not respond or experience a relapse.
- This study examined the expression of biomarkers like c-MYC, p53, and others in a cohort of 94 DLBCL patients to understand their correlation with patient outcomes and tumor characteristics.
- Results showed that p53 overexpression was linked to poorer outcomes, while the “starry-sky” tissue pattern indicated better survival in certain high-risk DLBCL patients, suggesting that these biomarkers can help inform prognosis and treatment strategies.
Article Synopsis
- * Key chromosomal changes included deletions and trisomies, with a high rate of mutations in several genes like TP53 and MYD88; researchers identified three risk groups based on these genetic alterations.
- * The study suggests that using specific drug combinations targeting MYC may enhance treatment effectiveness, and that cytogenetic analysis can aid in diagnosing and predicting outcomes in B-PLL.
We here report for the first time that low levels of interleukin (IL)-10 do not exclude lymphomatous meningitis (LM) in B-cell lymphoproliferative disorders (CLPD). Unexpectedly, IL-10 levels and IL-10:IL-6 ratio in CLPD differed from the levels observed in diffuse large B-cell lymphoma (DLBCL). We report the usefulness of adding the IL-10:IL-6 ratio in order to potentially reveal more aggressive lymphomas: either a transformation or an association with another "hidden" lymphoma such as primary CNS lymphoma (PCNSL).
View Article and Find Full Text PDFObjectives: This study investigates whether achieving complete remission (CR) with undetectable minimal residual disease (MRD) after allogeneic stem cell transplantation (allo-SCT) for chronic lymphocytic leukemia (CLL) affects outcome.
Methods: We retrospectively studied 46 patients transplanted for CLL and evaluated for post-transplant MRD by flow cytometry.
Results: At transplant time, 43% of the patients were in CR, including one with undetectable MRD, 46% were in partial response, and 11% had refractory disease.
No data are available on outcomes of patients with lymphoma requiring intensive care unit (ICU) admission. We retrospectively studied 190 patients admitted to our ICU between 2000 and 2010, before or during the first chemotherapy course for lymphoma. Reasons for ICU admission were renal failure (36%), shock (28%), respiratory failure (26%), coma (22%) and monitoring (12%).
View Article and Find Full Text PDFDeletions of the long arm of chromosome 14 [del(14q)] are rare but recurrently observed in mature B-cell neoplasms, particularly in chronic lymphocytic leukemia (CLL). To further characterize this aberration, we studied 81 cases with del(14q): 54 of CLL and 27 of small lymphocytic lymphoma (SLL), the largest reported series to date. Using karyotype and fluorescence in situ hybridization (FISH), the most frequent additional abnormality was trisomy 12 (tri12), observed in 28/79 (35%) cases, followed by del13q14 (12/79, 15%), delTP53 (11/80, 14%) delATM (5/79, 6%), and del6q21 (3/76, 4%).
View Article and Find Full Text PDF